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Abstract
Gyrate atrophy (GA) of the choroid and retina is a rare autosomal recessive disorder that occurs due to deficiency of the mitochondrial enzyme or-
nithine aminotransferase (OAT). Hyperornithinemia causes degeneration of the retina with symptoms like myopia, reduced night vision and progre-
ssive vision loss. Our patient is a 10-year-old girl with impaired vision and strabismus. As part of the metabolic work-up, plasma amino acid analysis 
revealed significantly increased concentration of ornithine (1039 μmol/L; reference interval 20 - 155 μmol/L). Molecular genetic analysis revealed 
homozygous mutation in exon 7 of the OAT gene that has not been reported previously (c.868_870delCTT p.(Leu290del)). This in frame deletion 
was predicted to be deleterious by in silico software analysis. Our patient was treated with pyridoxine (vitamin B6 in a dose of 2 x 100 mg/day), 
low-protein diet (0.6 g/kg/day) and L-lysine supplementation which resulted in a significant reduction in plasma ornithine concentrations to 53% 
of the initial concentration and the ophthalmologic findings showed significant improvement. We conclude that low protein diet and lysine supple-
mentation can lead to long-term reduction in plasma ornithine concentrations and, if started at an early age, notably slow the progression of retinal 
function loss in patients with GA. The effect of therapy can be reliably monitored by periodical measurement of plasma ornithine concentration. To 
our knowledge, this is the first report of OAT deficiency in Croatia.
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Case report
Introduction 
Gyrate atrophy (GA) of the choroid and retina 
(OMIM: 258870) is an inherited disorder of ornith-
ine metabolism characterized by slowly progres-
sive vision loss (1). This condition is caused by mu-
tations in the ornithine aminotransferase (OAT) 
gene and is inherited in an autosomal recessive 
manner, resulting in significantly reduced activity 
of mitochondrial enzyme ornithine aminotrans-
ferase (OAT; EC 2.6.1.13) (2). As a consequence, pa-
tients have markedly elevated concentrations of 
ornithine (10 to 15 times higher than normal) in 
plasma and other body fluids (3). Ornithine ami-
notransferase utilizes pyridoxal 5-phosphate, an 
active form of vitamin B6 as a co-factor and is ex-
pressed in most tissues, including kidney, small in-
testine, liver, and retina (4).
The OAT gene analysis is helpful for diagnosing pa-
tients with suspected GA. This gene encodes the 
mitochondrial enzyme OAT which is a key enzyme 
in the pathway that converts arginine (Arg) and or-
nithine (Orn) into glutamate (Glu) (5). The OAT pro-
tein is coded by a single gene, located on chromo-
some 10, region q26 (6). The primary transcript of 
the OAT gene is 21 kb long and contains 11 exons 
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(7). Translation starts in exon 3 and seems to oc-
cur on free polysomes (8). To date, 68 pathogenic 
mutations have been identified on ClinVar’s web-
site, plus 36 likely pathogenic, 25 of uncertain sig-
nificance, 3 likely benign and 4 benign mutations (9).
The clinical manifestation of GA usually starts with 
deterioration in visual acuity and night vision, fol-
lowed by the appearance of sharply demarcated, 
circular areas of chorioretinal atrophy with hyper-
pigmented margins in the midperiphery of the 
fundus (10). During the second and third decade 
of life the areas of atrophy enlarge and the ocular 
damage becomes irreversible. By the end of the 
second decade, most patients with GA develop 
cataract (11). These progressive vision changes 
usually lead to blindness in the fifth or sixth dec-
ade of life. The exact mechanism of chorioretinal 
degeneration remains unknown but it is believed 
to be due to a toxic effect of ornithine or one of its 
metabolites. Gyrate atrophy is a genetic disorder 
with increased incidence in Finland, estimated at 
1:50,000 (10). Treatment options include dietary 
supplements and/or a specialized diet. The main 
source of Orn is dietary Arg, and restriction of Arg 
in the diet appears to have a therapeutic effect (12).
The aim of this case report is to present the follow-
up of treatment of a 10-year-old girl with GA and 
points out the importance of regular measuring of 
amino acid concentrations during the patient’s fol-
low-up. 
Materials and methods
Subject
Here we present a case of a 10-year-old girl with 
GA and bilateral cystoid macular oedema. First 
symptoms in our patient appeared at the age of 
four when she experienced partial vision loss and 
strabismus in General Hospital Pula, Croatia. No 
other family member has reported any eye prob-
lems and her parents were both healthy and unre-
lated. At the age of six years, large retinal atrophic 
area was observed and GA of the choroid and reti-
na was suspected. Because of this characteristic 
ophthalmologic finding, she was further evaluated 
in the University Hospital Centre Zagreb, Croatia 
under suspicion of OAT deficiency. Ophthalmolog-
ic findings, optical coherence tomography (Coper-
nicus, Optopol Technologies, Zawierci, Poland) 
and fluorescein angiography (Visucam 500, Carl 
Zeiss Meditec, Jena, Germany) revealed bilateral 
macular oedema, with numerous circular sharply 
limited atrophic zones in the retina (Figure 1). 
Therapy with systemic corticosteroids and topical 
carbonic anhydrase inhibitors was administered. 
Further diagnostic workup by a psychologist 
showed significant attention-deficit with normal 
intellectual functioning. Signed informed consent 
was obtained from the patient’s parents.
Therapy
The therapy was divided into three phases. During 
the first phase, pyridoxine was given at the dose of 
Figure 1. Bilateral cystoid macular oedema - optical coherence 
tomography (A,B), fluorescein angiography (C,D) and peripher-
al fundus with numerous circular sharply limited atrophic zones 
in the retina - fluorescein angiography (E,F).  
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500 mg daily with unsatisfactory clinical and bio-
chemical effect. Plasma Orn concentration was 
measured at two-month intervals while the pa-
tient was fasting. In the second phase of therapy, 
the dose of pyridoxine was lowered to 2 x 100 mg 
daily and a low protein diet was implemented (at 
first, 1 g/kg/day of natural protein that was further 
gradually lowered to 0.6 g/kg/day). Lastly, during 
the third phase of treatment, the amino acid L-ly-
sine was additionally administered. L-lysine was 
given in rising dosages from 6 to 12 g daily. The 
goal was to increase the excretion of Orn and Arg 
by urine in order to reduce plasma Orn concentra-
tion as low as possible.
Sample collection 
Whole blood was taken on two different anticoagu-
lants, K3/K2-EDTA and lithium heparin, and in serum 
gel tubes (Greiner Bio-One GmbH®, Kremsmünster, 
Austria). For ammonia measurement, samples were 
collected and immediately put on ice after ve-
nepuction. Plasma and serum were removed from 
the cells by centrifugation at 2500xg for 10 minutes 
at room temperature (Thermo Scientific™, Oster-
ode, Germany) within a few hours after blood col-
lection and analysed immediately. Samples for ami-
no acid analyses were taken in 5 mL tubes about 
four hours after meals. Urine samples were collect-
ed in 10 mL tubes without additives (Greiner Bio-
One GmbH®, Kremsmünster, Austria).
Biochemical and haematological analysis
Before starting therapy, complete blood count 
was performed using UniCel® DxH 800 Coulter® 
analyser (Beckman Coulter Inc., Brea, CA, USA). For 
routine biochemical analyses, Cobas c501/c311 
(Roche Diagnostics®, Basel, Switzerland) was used. 
Quantitative amino acid analysis
Amino acids were measured with liquid chroma-
tography coupled with electrospray tandem mass 
spectrometry LC-MS/MS (UPLC Nexera, Shimadzu, 
Canby, OR, USA; API 3200, Sciex, Framingham, MA, 
USA). The use of aTRAQ™ kit for physiological ami-
no acid analysis (Sciex, Framingham, MA, USA) al-
lows quantitation of free amino acids in plasma 
and urine. Cliquid Software in conjunction with 
Analyst® Software (Sciex) applications was used to 
obtain data for the quantification of up to 45 ami-
no acids. The instrument automatically calculates 
the concentration of amino acids in each sample. 
The values obtained from the urine sample must 
be divided by the creatinine concentration (mmol/
mol creatinine). 
Preparation of the samples was made according to 
manufacturer’s instructions using 40 μL of physio-
logical fluids. They were introduced firstly into a liq-
uid chromatographic system where they were sep-
arated on a chromatographic column (AAA C18 Col-
umn, 4.6x150 mm, Sciex, Framingham, MA, USA), 
and then into a mass spectrometer where they 
were ionized, fragmented and further separated. 
The ionized fragments were detected based on 
mass and ion charge ratio (m/z). Every ionized frag-
ment generated was characterized by specific re-
tention time. The individual amino acids were iden-
tified by characteristic fragments with specific mass 
transitions (m/z), while the quantitative analysis was 
performed by comparing the intensity of the pa-
tient amino acid ion with the corresponding inter-
nal standard (amino acid concentration) (Figure 2). 
Molecular genetic analysis
In order to confirm the diagnosis, a DNA sample of 
the patient was analysed in a collaborative labora-
tory (Division of Metabolism, University Children’s 
Hospital, Zürich, Switzerland). Genomic DNA was 
extracted from 1 mL whole blood using FlexiGene 
DNA Kit (Qiagen, Crawley, UK). Polymerase chain 
reaction (PCR) was carried out using the HotStar 
Taq DNA Polymerase kit (Qiagen, Hombrechtikon, 
Switzerland) on a Biometra T-Professional thermo-
cycler (Biometra GmbH, Göttingen, Germany) with 
following cycling conditions: 1 cycle of 15 min at 
95°C, followed by 35 cycles of 30 sec at 95°C, 20 
sec at 63°C and 1 min at 72°C, and finishing with 7 
min incubation at 72°C. The OAT coding exons in-
cluding the flanking intronic regions were ampli-
fied by PCR using the following primers (Table 1). 
The size and quality of DNA fragments obtained 
was analysed by 2% agarose-gel-electrophoresis 
with EZ Vision One dye (VWR Amresco, Dietikon, 
Biochem Med (Zagreb) 2018;28(3):030801  https://doi.org/10.11613/BM.2018.030801 
4
Zekušić M. et al. Metabolic follow-up of a Croatian patient with gyrate atrophy 
Figure 2. High intensity peak of ornithine (Orn) was found by comparing the patient’s plasma amino acid chromatogram (A) with a 
chromatogram of the internal standard (B)
A
B
Orn
Orn
Exon Primer (5,----3,)
Forward Reverse
Exon 2 Fwd 5’-GTGATGGAGTCTTGCTCTGTTGC-3’ Exon 2 Rev 5’-CCATGTCTGCAATATACAC-3’, 
Exon 3/4 Fwd 5’-GTGTGTTTTGAAGCTGGGCAG-3’, Exon 3/4 Rev 5’-GAAGGCTGGTCTTGAACTCCAG-3’,
Exon 5 Fwd 5’-GAAGGTGCACTAAAGCAAGCC-3’, Exon 5 Rev 5’-GAGAACAAGTCTGAAATCGTGGC-3’, 
Exon 6 Fwd 5’-GGCAGTGAATTTGAAGTCAG-3’, Exon 6 Rev 5’-GCTCTTAGAATGCCATCGC-3’, 
Exon 7 Fwd 5’-GAGGGCACATCAGAATTACAC-3’, Exon 7 Rev 5’-AGGCACACTCAATTCTTCAG-3’, 
Exon 8 Fwd 5’-GAGTCCAGGAGGCAGAGATTG-3’, Exon 8 Rev 5’-GAGGAAATCCAGTCTACTAGG-3’, 
Exon 9 Fwd 5’-GCAAGACTCTGAGCTAGTGTATG-3’, Exon 9 Rev 5’-CTGAGGCAGAGAATTGCTTG-3’, 
Exon 10 Fwd 5’-CAATCTCTTGACCTCGTGATCC-3’, Exon 10 Rev 5’-CGGCAGGTTCATAAACGTTG-3’. 
Table 1. Primer sequences
Switzerland) in 5 x TBE buffer (45 mM Tris-borate, 
1mM EDTA) at 100 V for 35 minutes. DNA frag-
ments were visualized using the AlphaImager HP 
gel imaging system (Bio-Techne AG, Zug, Switzer-
land) under UV light wavelength of 365 nm. After 
agarose gel electrophoresis PCR products were 
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Sanger sequenced according to standard proto-
cols using the BigDye Terminator Cycle Sequenc-
ing kit v1.1 and an ABI 3130 Genetic Analyser (Ap-
plied Biosystems by Life Technologies Europe BV, 
Zug, Switzerland). Sequencing raw data were ana-
lyzed using the SeqPatient module of the SE-
QUENCE PILOT software (JSI Medical Systems, 
Ettenheim, Germany) using the following refer-
ence sequences: OAT Ensembl ENSG00000065154 
and ENST00000368845.5. Nomenclature of the 
mutation follows the recommendations of the Hu-
man Genome Variation Society (13) and was 
checked using the online software Mutalyzer (14).
Results
Routine biochemical analysis and complete blood 
count results were within normal range (Table 2), 
except creatinine and ammonia that were below 
normal range (creatinine 23 µmol/L, reference in-
terval 25 - 42 µmol/L; ammonia 20.9 µmol/L, refer-
ence interval 24.0 - 48.0 µmol/L).
Quantitative analysis of amino acids in plasma is 
necessary for patients suspected to have hyperor-
nithinemia. Our patient had significantly increased 
initial concentrations of Orn (1039 μmol/L; refer-
ence interval 20 - 155 μmol/L) (Table 3). 
During the first phase of therapy, laboratory re-
sults of quantitative analysis of amino acids 
showed only a discrete decline in Orn concentra-
tion (13%). In the second phase of therapy, the de-
crease of plasma Orn was more significant (48%). 
The decrease of bilateral cystoid macular oedema 
was transient and the progression of peripheral 
atrophic lesions continued. During the third phase 
of treatment, adequate reduction of plasma Orn 
was achieved (53%) (Figure 3). 
This resulted in increase of plasma lysine (Lys) con-
centration over the next two years from 74 to 218 
μmol/L (reference interval 50 - 284 μmol/L) (Table 3). 
Ornithine excretion in urine was measured at four-
month intervals. Adding L-lysine supplement to a 
low protein diet resulted in increased excretion of 
Orn (153 mmol/mol creatinine, reference interval 0 
- 7), Arg (36 mmol/mol creatinine, reference inter-
val 0 - 7) and several other amino acids such as as-
Analyte Results Unit Reference interval
Urea 3.0 mmol/L 1.8 - 6.0
Creatinine 23 µmol/L 25 - 42
Ammonia 20.9 μmol/L 24.0 - 48.0
K 4.7 mmol/L 3.6 - 5.0
Na 137 mmol/L 134 - 143
Cl 102 mmol/L 96 - 109
Ca 2.41 mmol/L 2.15 - 2.80
P 1.35 mmol/L 1.11 - 1.73
Mg 0.77 mmol/L 0.65 - 1.03
Albumin 47.2 g/L 35.0 - 52.0
Transferrin 2.38 g/L 2.00 - 3.60
RBC 4.58 x1012/L 4.00 - 5.00
Hb 127 g/L 109 - 138
Hct 0.373 L/L 0.320 - 0.404
MCV 78.3 fL 73.8 - 89.4
MCH 26.8 pg 24.3 - 29.2
MCHC 342 g/L 300 - 350
RDW 14.1 % 9.0 - 15.0
Rtc 9.1 /1000 RBC 4.0 - 19.0
Rtc 43 x109/L 22 - 97
IRF 0.3 0.1 - 0.3
WBC 5.4 x109/L 5.0 - 13.0
Eosinophils 3 % 0 - 6
Segmented 
Neutrophils 51 % 30 - 72
Lymphocytes 33 % 15 - 55
Monocytes 13 % 5 -13
Eosinophils 0.16 x109/L 0.00 - 0.70
Segmented 
Neutrophils 2.75 x10
9/L 1.40 - 8.00
Lymphocytes 1.78 x109/L 1.40 - 5.00
Monocytes 0.70 x109/L 0.22 - 1.51
PLT 198 x109/L 150 - 450
MPV 8.9 fL 6.9 - 11.3
K - potassium. Na - sodium. Cl - chloride. Ca - calcium. P - 
inorganic phosphates. Mg - magnesium.RBC - red blood cell 
count. Hb - haemoglobin. Hct - haematocrit. RDW - red cell 
distribution width. MCV - mean corpuscular volume. MCH - 
mean corpuscular haemoglobin. MCHC - mean corpuscular 
haemoglobin concentration; Rtc - reticulocytes. IRF - 
immature reticulocytes fraction. WBC - white blood cell count. 
MPV - mean platelet volume. PLT - platelet count.
Table 2. Patient’s biochemistry and complete blood count test 
results
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Amino acids Reference interval (µmol/L)
Before treatment 
(µmol/L)
After treatment (µmol/L)
First phase (vit.B6 
500 mg/day)
Second phase (vit.
B6 200 mg/day and 
low-protein diet)
Third phase (vit.B6 200 
mg/day, low-protein 
diet and L-lysine)
Orn 20 - 155 1039 907 537 489
Ala 130 - 547 250 229 506 642
Arg 10 - 140 79 81 66 58
Asn 20 - 112 47 47 53 49
Asp 0 - 20 4 4 4 4
Cit 1 - 46 31 31 23 26
Gln 254 - 823 518 637 568 629
Glu 10 - 150 21 17 18 16
Gly 110 - 343 194 163 251 199
His 41 - 125 63 68 78 87
Hyp 0 - 45 26 28 21 15
Ile 22 - 107 61 68 43 39
Leu 49 - 216 110 125 75 75
Lys 50 - 284 74 72 201 218
Met 15 - 45 - 0 - 23
Phe 26 - 91 46 51 47 40
Pro 60 - 340 166 202 207 187
Ser 70 - 194 141 133 164 112
Tau 20 - 170 32 30 48 40
Thr 35 - 226 134 135 94 86
Tyr 25 - 115 58 65 51 36
Val 80 - 321 209 216 164 131
Orn - ornithine. Ala - alanine. Arg - arginine. Asn - asparagine. Asp - aspartic acid.  Cit - citrulline. Gln - glutamine. Glu - glutamic 
acid. His - histidine. Hyp - hydroxyproline. Ile - isoleucine. Leu - leucine. Lys - lysine. Met - methionine. Phe - phenylalanine. Pro - 
proline. Ser - serine. Thr - threonine. Tyr - tyrosine. Val - valine.
Table 3. Long-term follow-up: plasma amino acids in the patient with gyrate atrophy
paragine (Asn) (203 mmol/mol creatinine, refer-
ence interval 0 - 29), Lys (235 mmol/mol creatinine, 
reference interval 10 - 68), and citrulline (Cit) (9 
mmol/mol creatinine, reference interval 0 - 5) in 
urine. In the third period during treatment with L-
lysine, urinary excretion of Orn was highly in-
creased. Administration of L-lysine increased renal 
excretion of Arg and Orn, which contributed to a 
decrease of plasma Orn. 
The reduction of plasma Orn was associated with 
a positive change in the patient’s electroretino-
grams. During the third phase of therapy, the oph-
thalmologic fundus examination showed signifi-
cant improvement (only discrete oedema of the 
macula was found). 
Molecular genetic analysis revealed the homozy-
gous mutation c.868_870delCTT in the exon 7 of 
the OAT gene resulting in the deletion of one ami-
no acid p.(Leu290del). So far, this mutation has not 
been described in the Human Gene Mutation Da-
tabase. The mutation (in frame deletion) was pre-
dicted to be pathogenic by in silico software: 
PROVEAN (Protein Variation Effect Analyser): score 
= - 10.25 (cut-off = - 2.5), prediction: deleterious.
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Discussion
Hyperornithinemia causes a permanent loss of ret-
inal cells (atrophy) with the symptoms like myopia 
and progressive deterioration of peripheral and 
night vision, eventually resulting in blindness (1). 
Most patients with a diagnosis of GA have no 
symptoms other than vision loss, but in some cas-
es neonatal hyperammonemia, intellectual disa-
bility, peripheral nerve problems and muscle 
weakness may occur (15). Our patient did not have 
any additional symptoms besides vision loss.
Besides high Orn concentration, low plasma con-
centrations of Lys, Glu, ammonia and creatinine 
are common characteristics of untreated GA (1). 
Our patient had mildly decreased concentrations 
of Lys and Glu (close to the lower reference limit). 
Plasma ammonia and creatinine were also reduced 
(below the reference interval). The reason for de-
creased concentration of ammonia and glutamate 
in untreated patients with GA is unknown.
An ordinary diet usually contains a high amount of 
protein, including amino acid Arg. However, Arg is 
an essential amino acid in GA patients and limita-
tion of dietary Arg might result in reduction of 
plasma and urine Orn (16). The reduction of Arg in-
take had only transient benefit in our patient. The 
most benefit was achieved when L-lysine was add-
ed to the treatment. The dose of L-lysine was grad-
ually increased until a plateau in ornithine plasma 
concentration was reached. In the study of Elpeleg 
et al. the administration of 10 - 15 g L-lysine daily 
for 40 - 55 days in three patients (ages 13 - 19) with 
gyrate atrophy decreased plasma Orn concentra-
tions by 21 - 31%. A daily dose of 15 g was more 
effective than 10 g (17). It has been described in 
the literature that less than 5% of patients with GA 
had been responsive to vitamin B6 (1,18,19). A slight 
decrease in plasma Orn concentration was ob-
served after supplementing vitamin B6 in our pa-
tient. 
Recently, a new diagnostic test based on proline/
citrulline ratio (Pro/Cit) in plasma and dried blood 
spot (DBS) in new-born screening laboratories 
was developed (20, 21). Deficiency of OAT causes 
an increase in Pro/Cit ratio. Ornithine and Arg con-
centrations in plasma/DBS are often abnormal in 
neonates with OAT deficiency (Pro is increased, Cit 
is reduced) (21,22). This theory supports the use of 
the Pro/Cit ratio on tandem mass spectrometry 
with the best diagnostic sensitivity and accuracy. 
Proline/citrulline ratio should be considered as a 
differential diagnostic tool in new-born screening 
Figure 3. Monitoring of plasma amino acid concentration during dosage adjustment. Ornithine values significantly differed be-
tween the first and third period of treatment. 
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allowing differential diagnosis for all new-borns 
with hyperammonemia suspected of OAT defi-
ciency (22). However, we have no possibility of ver-
ifying that information for our GA patient because 
our new-born screening laboratory in Croatia 
stores DBS for only five years. Current medical lit-
erature is lacking in data on early introduction of 
therapy in patients detected by new-born screen-
ing and patient’s follow-up. The reason for that 
could be relatively low disease incidence and 
probably low detection rate in less developed 
countries.
Patients with GA generally have normal intelli-
gence (23). One of described patients had mild 
mental retardation, delayed language develop-
ment, and speech defects (24). Our 10-year-old pa-
tient had normal intellectual functioning but with 
significant attention-deficit. 
Hyperornithinemia is the main pathogenic factor 
in GA and our case proves that it can be treated by 
low protein diet, supplementation of vitamin B6 
and L-lysine. To the best of our knowledge, this is 
the first report of GA in Croatian population. For 
the first time we introduce an approach of a step-
wise L-lysine dosage adjustment guided by regu-
lar plasma Orn quantification, which resulted in 
the highest plasma ornithine reduction reported 
in the literature. The diagnosis was confirmed by 
molecular genetic analysis, with a new homozy-
gous mutation detected in the OAT gene.
The purpose of this paper was to stress the impor-
tance of early diagnostics and treatment in GA. 
Laboratory professionals together with clinicians 
should consider introduction of new Pro/Cit ratio 
test in new-born screening programs since it could 
be valuable for the early diagnosis and treatment 
of GA patients, thus preventing occurrence of irre-
versible retinal changes. 
It should be acknowledged that there are several 
limitations in this case report. The follow-up peri-
od is relatively short to show long-term outcome 
of the treatment on patient’s vision, although oph-
talmological follow-up did show promising results. 
This is a follow-up study of only one patient. A 
larger number of treated patients might give us 
better insight into the efficacy of this treatment 
approach. As the disease is very rare (approximate-
ly 150 individuals with GA have been identified so 
far) multicentre collaboration would be needed to 
achieve that (18). For improvement of this study it 
should be useful to screen more subjects. The in-
troduction of new-born screening for OAT defi-
ciency should be helpful in early detection and 
early treatment introduction. Our patient is ho-
mozygous for a previously undescribed mutation 
expected to be pathogenic due to clear clinical 
phenotype (pathognomonic ocular changes), 
quantitative amino acid analysis and in silico analy-
sis. For final proof of pathogenicity, further func-
tional studies are needed to validate our results. 
As parental DNA was unavailable, we examined 
only our patient; consequently, it is not certain if 
this mutation is de novo mutation. Finally, Sanger 
sequencing by capillary electrophoresis was used. 
It is currently the most widely used routine molec-
ular analysis and is adequate for the majority of 
clinical applications involving the analysis of single 
genes. The method is rapid, robust and known as 
a gold standard for clinical research sequencing 
with 99.9% accuracy, so it was not necessary to 
confirm this mutation with a second different mo-
lecular analysis (25).
In conclusion, if therapy for GA is introduced at an 
early age, along with long-term monitoring of 
plasma Orn concentrations, the progression of ret-
inal function loss may be notably delayed. Com-
bined treatment with low protein diet, L-lysine and 
pyridoxine supplementation in our patient result-
ed in plasma Orn decrease to 53% of the initial 
concentration and a significant improvement of 
ocular changes. Although longer follow-up is 
needed to estimate true benefits of this treatment, 
we find results presented in this paper very en-
couraging. 
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